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Background: Paraquat, still used as an herbicide in some parts of the world, is now regarded as a dangerous
environmental neurotoxin and is linked to the development Parkinson’s disease (PD). Paraquat interacts with cellular
redox systems and causes mitochondrial dysfunction and the formation of reactive oxygen species, which in turn,
plays a crucial role in the pathophysiology of PD. Various antioxidant therapies have been explored with the
expectations that they deliver health benefits to the PD patients, however, no such therapies were effective. Here
we have tested the neuroprotective efficacy of a novel water-soluble CoQ10 (Ubisol-Q10), in a rat model of
paraquat-induced neurodegeneration in order to evaluate its potential application in the management of PD.
Results: We have developed a rat model of progressive nigrostriatal degeneration by giving rats five intraperitoneal
injections of paraquat (10 mg/kg/injection), once every five days. Neuronal death occurred over a period of 8 weeks
with close to 50% reduction in the number of tyrosine hydroxylase-positive cells. Ubisol-Q10, at 6 mg CoQ10/kg
body weight/day, was delivered as a supplement in drinking water. The intervention begun after the completion of
paraquat injections when the neurodegenerative process had already began and about 20% of TH-positive neurons
were lost. Ubisol-Q10 treatment halted the progression of neurodegeneration and remaining neurons were
protected. The outcomes were evaluated based on the number of surviving tyrosine hydroxylase-positive neurons
in the substantia nigra region and improved motor skills in response to the Ubisol-Q10 intervention. To maintain this
neuroprotection, however, continuous Ubisol- Q10 supplementation was required, if withdrawn, the neuronal death
pathway resumed, suggesting that the presence of CoQ10 was essential for blocking the pathway.
Conclusion: The CoQ10, given orally as Ubisol-Q10 in drinking solution, was effective in blocking the progression of
neurodegeneration when administered therapeutically (post-toxin injection), at a much lower concentration than
other previously tested oil soluble formulations and well within the acceptable daily intake of 12 mg/kg/day. Such
unprecedented neuroprotection has never been reported before. These results are very encouraging and suggest
that Ubisol-Q10 should be further tested and developed as a therapy for halting the progression of PD.
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Parkinson’s disease (PD), the second most common neu-
rodegenerative disorder, is characterised by the loss of
dopaminergic (DA) neurons in the substantia nigra pars
compacta (SNpc) region of the brain. PD affects approxi-
mately 1–2% of the population, above the age of 55 and
with the steady growth of the ageing population, disease
management is a growing concern for neurologists and
other physicians. By the time the characteristic features of
PD such as bradykinesia, rigidity, postural instability, and
resting tremor become obvious, approximately 60-70% of
DA neurons in the SNpc are lost [1]. Currently, there is
no therapy available to halt the progression of this neuro-
degeneration. It has been possible, however, to alleviate
the symptoms of the disease by providing dopamine re-
placement. Administration of levodopa is the most com-
monly utilized treatment for symptomatic relief [2], yet its
prolonged application leads to drug induced dyskinesia,
which severely affects the patient’s quality of life.
In the majority of cases the cause of PD remains un-
known, but factors contributing to the pathogenesis of
the disease are extensively studied. PD can be caused by
environmental factors such as exposure to herbicides and
pesticides or by genetic factors linked to gene mutations
that increase the susceptibility to PD [3]. Although these
genetic defects account for only 10% of PD cases, their
identification brings about a better understanding of the
disease pathophysiology and its progressive nature [4]. It
is known that classical symptoms of PD can be caused by
exposure to neurotoxin MPTP. In 1983 Langston’s group
found PD like symptoms in young drug addicts who con-
sumed heroin containing MPTP, a by-product in the syn-
thesis of a synthetic heroin [5]. Later it was shown that
MPTP injections cause selective loss of DA neurons in the
SNpc region of certain strains of mice thereby creating
animal models of PD [6-9]. Although MPTP is not an en-
vironmental toxin and humans are not commonly ex-
posed to it, several epidemiological studies reveal a link
between the use of herbicides and pesticides such as para-
quat (PQ), maneb and rotenone and the incidence of PD
[10]. It was subsequently discovered that the active metab-
olite of MPTP, MPP + and PQ have structural similarity.
They enter the DA neurons via the dopamine transporter
as well as trigger neurodegeneration [11]. Three independ-
ent studies in Texas, Taiwan and California show that
exposure to PQ indeed causes an increased susceptibility
to PD [12,13]. In rodents, PQ exposure leads to the loss of
DA neurons in the SNpc region of the brain in a time and
dose dependent manner [14]. Therefore, rat and mouse
models of PQ-induced neurodegeneration have been de-
veloped to study the pathophysiology of the disease and to
develop successful treatment strategies.
One consistent finding between the PD patients and
animal models of PD (MPTP, PQ, rotenone) is themalfunctioning of complex I of the electron transport
chain suggesting clearly, that mitochondrial dysfunction is
at the centre of PD pathophysiology [4]. It seems that a
blockade of complex I of the oxidative phosphorylation
pathway by these toxins and the inability of DA neurons to
cope with the excess of generated free radicals are the trig-
gers of neuronal death. Therefore, it should be possible to
interfere with the progression of neurodegenerative pro-
cesses by applying antioxidants, such as CoQ10 and/or
Vitamin E, which are capable of reducing the levels of free
radicals. However, both these antioxidants are lipid soluble
compounds, characterized by limited bioavailability and
difficult to deliver systemically, especially to the brain. Nu-
merous studies have shown that CoQ10 is effective in pre-
venting cell death caused by toxins such as PQ, however,
very high doses of CoQ10 (from oil soluble formulation
available on the market) are required to provide neuropro-
tection in vivo [15]. Our collaborators at NRC (Ottawa,
ON) have developed a nanomiscelle formulation of CoQ10
(Ubisol-Q10), which appears water soluble and contains
CoQ10 and a derivatized form of α-tocopherol (vitamin E)
[16,17]. The solubilization of CoQ10 is achieved due to
amphipathic properties of PEG-derivatised α-tocopherol
allowing the formation of stable and water soluble nanomi-
celles [16,17]. This formulation has been tested in several
cell culture models and it has been shown to be efficient in
protecting neurons from the toxic effects of PQ [18]. It has
also been tested in vivo in rats exposed to PQ [14]. Prophy-
lactic application of Ubisol-Q10 in this rat model of PD,
provided as drinking solution prior to the PQ exposure
and throughout the duration of experiments, clearly con-
firm its neuroprotective efficacy against PQ. The beneficial
effects were achieved at a much lower dose of CoQ10
(6 mg/kg b.w.) compared to oil soluble formulation, which
was used at 200 – 1600 mg/kg/day in mice [19].
Since PD is diagnosed when the symptoms appear and
the neurodegeneration is already in progress, the prophy-
lactic treatments, especially in sporadic cases of PD, are
not relevent. Therefore, we designed a study to examine
whether a therapeutic intervention with Ubisol-Q10 in rats
already exposed to PQ could halt the on-going neurode-
generation and behavioural deterioration. Furthermore,
we investigated whether a sustained supplementation of
Ubisol-Q10 was needed to maintain the neuroprotec-
tion. Here we present our data showing that oral deliv-
ery of Ubisol-Q10, starting after the PQ injections, did
halt neurodegeneration and prevented a loss of normal
motor skills.
Results
Brain delivery of Coenzyme Q10
The brain CoQ10 levels were measured in rats which
were given a 1 h access to Ubisol-Q10 supplemented
water (at a concentration of 50 μg /ml) after a 24 h
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on average 10 ml of solution containing 500 μg of
CoQ10. Animals were sacrificed at different time points
after the Ubisol-Q10 intake, CoQ10 was extracted and
analysed by HPLC. The results are shown in Figure 1.
We observed a modest, but time dependent elevation of
CoQ10 in the brain, peaking at 3 h post-feeding, with
values 30-50 % higher than the basal level, suggesting
that its transfer to the brain parenchyma and subse-
quent metabolic turnover was taking place. A question
whether these changes were sufficient to achieve a
therapeutic neuroprotection against PQ was examined
below (Figures 2, 3 and 4).
Paraquat model of progressive neurodegeneration
Long Evans Hooded rats were used to develop a model of
progressive neurodegeneration. The rats were given 5 in-
traperitoneal injections of PQ (10 mg/ kg b.w./injection),
one injection every five days over a period of 20 days. Ani-
mals were sacrificed at different time points for up to
8 weeks post-PQ exposure. Midbrain sections were pre-
pared, immunostained with anti-tyrosine hydroxylase anti-
body and TH- positive neurons were counted using a
stereologer, in an unbiased manner. As shown in Figure 2,
a substantial percentage of DA neurons, i.e., close to 18%,
were lost during the PQ injection period (PQ1 group).
The neurons continued to die over the next several weeks
reducing the number of TH-positive neurons by 43% at
the end of week 4 (PQ2 group) and 47% by end of week 8
(PQ3 group) post-PQ exposure. The results confirmed
that PQ triggered progressive neurodegeneration in this
strain of rats, mimicking to some extent, changes occur-
ring in Parkinsonian patients. This model is probably
closest to what happens in humans as one month in a
rat’s lifetime is equivalent to 2.5 years in human [20].Figure 1 Bioavailability of Ubisol – Q10. (A) There is a gradual increase i
and 3 hour time points following the 1 hour feeding with Ubisol – Q10 sup
comparison with the control group that was fed with regular drinking wat
the water feeding. (B) There is a 25% increase in the level of CoQ10 at the
at the 6 hour time point.Therefore, this model was used to assess a therapeutic
neuroprotection of CoQ10.
Therapeutic intervention with Ubisol-Q10
We have previously shown that prophylactic treatment
with Ubisol – Q10 effectively protects rat brain from PQ
toxicity [18]. In this study we applied the Ubisol-Q10 inter-
vention after the completion of PQ injections. By this
time, neurodegenerative processes in the brain had already
triggered (Figure 2). The PQ-treated group of rats was
placed on Ubisol-Q10 supplemented drinking water (con-
taining 50 μg/ml of CoQ10) for 4 weeks (PQ2 + 4 wks
Ubisol-Q10 group). This treatment began when nearly
18% of SN neurons were already lost (PQ1 group,
Figure 2), but the question was whether the remaining
vulnerable neurons could be saved. The generated data is
summarized in Figure 3. The midbrain sections were im-
munostained with anti- TH antibodies, and the stained
neurons were counted using a stereologer in an unbiased
manner. As shown above (Figure 2), the PQ- treated rats
drinking regular water (PQ2 group) lost over 40% of DA
neurons over the period of 4 weeks, whereas rats drinking
Ubisol – Q10 lost less than 20% (PQ2 + 4 wks Ubisol-Q10
group). Clearly, this Ubisol-Q10 treatment saved close to
17% of neurons which would have otherwise died as the
consequence of PQ exposure. This unprecedented neuro-
protection has never been reported in animal models of
neurotoxicity and could offer hope to PD patients for bet-
ter disease management.
We then examined how long Ubisol – Q10 supplemen-
tation would be required to maintain neuroprotection.
In this set of experiments the PQ treated rats were ei-
ther kept on Ubisol – Q10 for the full 8 weeks post-PQ
or the treatment was withheld after 4 weeks and rats
were given regular tap water for the additional 4 weeksn the levels of CoQ10 in the rat brains that were sacrificed at the 1
plemented drinking water after the 24 hour water starvation in
er for 1 hour instead. The control group was sacrificed 1 hour following
1 hour time point, 34% at the 3 hour time point and a decline to 16%
Figure 2 Progressive loss of DA neurons following PQ injections. (A) The experimental plan demonstrating the injection regime and
treatment schedule. Immunohistochemistry performed using anti-tyrosine hydroxylase antibodies on the brain sections of animals. (B)
Representative images of midbrain sections showing TH positive neurons at lower and higher magnifications from saline injected control group
rats, PQ injected rats dissected 24 hours after the last injection (PQ1 group), PQ injected rats dissected four weeks after the last injection (PQ2
group), PQ injected rats dissected eight weeks after the last injection (PQ3 group). The area of SN which is to be counted is selected in every 6th
section of the midbrain (sectioned at 30 microns thickness). (C) The total number of TH positive neurons in the SNpc region was counted at
higher magnification using the stereology software purchased from the Stereology Resource Centre, Inc., Florida. There is a significant decrease in
the number of TH - positive neurons (*p < 0.05) in the rats sacrificed four weeks and (**p < 0.05) eight weeks after the last injection in comparison
with saline injected control group and no significance in rats sacrificed immediately after the last injection verses saline injected control groups.
(D) The percentage decrease in TH positive neurons between the saline injected control and PQ groups. There is 43.3% and 47% decrease in the
TH positive neurons in the rats sacrificed four and eight weeks after the last injection and only a 17.8% decrease in the number of TH positive
neurons in the rats sacrificed 24 hours after the last injection. The bars in the upper (low magnification) panel are 200 μm and in the lower (high
magnification) panel 20 μm.
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rons, approximately 47% in comparison with the saline
injected control group indicating progressive neurode-
generation over a period of eight weeks (Figure 4). There
was also significant neuroprotection in the rats that re-
ceived the Ubisol – Q10 supplemented drinking water
for eight weeks post injections. Since the Ubisol – Q10
intervention began after nearly 15% of DA neurons werealready killed (Figure 2) no further loss of neurons was
observed as a result of this intervention (Figure 4, only
14% of neuronal loss recorded). However, if the treat-
ment was withheld after 4 weeks, the neurodegeneration
resumed as evidenced by the reduced number of surviving
neurons in this experimental group comparing to the
group receiving Ubisol – Q10 for 8 weeks (28% versus
14%, respectively). Therefore, continuous Ubisol – Q10
Figure 3 Halting the progression of neurodegeneration by Ubisol – Q10. (A) The experimental plan demonstrating the injection regime
and treatment schedule. Immunohistochemistry performed using anti-tyrosine hydroxylase antibodies on the brain sections of animals. (B)
Representative images of midbrain sections showing TH positive neurons at lower and higher magnifications from saline injected control group
rats, PQ injected rats fed with regular drinking water dissected immediately after the last injection (PQ1), PQ injected rats fed with regular drinking
dissected 4 weeks after last injection (PQ2), PQ injected rats fed with Ubisol – Q10 supplemented drinking water after last injection and dissected
4 weeks after last injection (PQ2 + Ubisol- Q10 4 weeks). The area of SN which is to be counted is selected in every 6
th section of the midbrain
(sectioned at 30 microns thickness). The total number of TH positive neurons in the SNpc region was counted at high magnification using the
stereology software purchased from the Stereology Resource Centre, Inc., Florida. (C) The percentage decrease in TH positive neurons between
the saline injected control group and the PQ injected treated and untreated groups. There is a significant 41% decrease in the TH positive
neurons in the PQ2 group in comparison with the saline injected control group (*p < 0.05), whereas there is loss of 17% neurons in the Ubisol –
Q10 treated group verses the control (**p < 0.05) indicating significant neuroprotection when compared to the PQ2 group. The bars in the upper
(low magnification) panel are 200 μm and in the lower (high magnification) panel 20 μm.
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Figure 4 (See legend on next page.)
Muthukumaran et al. BMC Neuroscience 2014, 15:21 Page 6 of 11
http://www.biomedcentral.com/1471-2202/15/21
(See figure on previous page.)
Figure 4 Sustained feeding of Ubisol-Q10 is needed for neuroprotection. (A) The experimental plan demonstrating the injection regime
and treatment schedule. (B) Immunohistochemistry performed using anti-tyrosine hydroxylase antibodies on the brain sections of animals.
Representative images of midbrain sections showing TH positive neurons at lower and higher magnifications from saline injected control group
rats, PQ injected rats fed with regular drinking water dissected 8 weeks after last injection (PQ3), PQ injected rats fed with Ubisol – Q10 supple-
mented drinking water for 4 weeks followed by regular drinking water for 4 weeks after last injection with PQ and dissected 8 weeks after last
injection (PQ3 + Ubisol – Q10 4 weeks group), PQ injected rats fed with Ubisol – Q10 supplemented drinking water for 8 weeks after last injection
with PQ and dissected 8 weeks after last injection (PQ3 + Ubisol – Q10 8 weeks group). The area of SN which is to be counted is selected in every
6th section of the midbrain (sectioned at 30 microns thickness). The total number of TH positive neurons in the SNpc region was counted at high
magnification using the stereology software purchased from the Stereology Resource Centre, Inc., Florida. (C) The percentage decrease in TH
positive neurons between the saline injected control and PQ injected treated and untreated groups. There is a significant 47% decrease in the
TH positive neurons in the PQ3 group in comparison with the saline injected control group (*p < 0.05) and loss of 28% neurons in the PQ3 +
Ubisol-Q10 4 weeks group. A 14% decrease in TH positive neurons is seen in the treated PQ3 + Ubisol-Q10 8 weeks (**p < 0.05) indicating
significant neuroprotection when compared to the PQ3 group. The bars in the upper (low magnification) panel is 200 μm and in the lower (high
magnification panel) 20 μm.
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level of neuroprotection.
Behaviour results
Deficiency in the motor function is a hallmark of PD.
Next, we asked whether loss of DA neurons correlated
with the deficiency of behavioural motor function follow-
ing PQ treatment, and whether motor deterioration was
blocked by Ubisol-Q10 treatment. We applied a horizontal
beam walking test as described in the Method section. Re-
sults shown in Figure 5 indicated that the PQ3 group
made more leg slips than either the control or the PQ3 +
Ubisol-Q10 8 weeks in both the test phases or than the
PQ3+ Ubisol-Q10 4 weeks group in the first test phase.
The PQ3 + Ubisol-Q10 4 weeks increased its leg slips to
the elevated levels of the PQ3 group in the second test
phase. Multiple comparisons between groups confirmed
that the number of leg slips of the PQ3 group was sig-
nificantly greater than those of the other three groupsFigure 5 Mean total number of hind leg slips over three sessions
in each post-injection test for each Injection/Treatment group.
Vertical error lines represent ± SEM. Significant difference (p < 0.05)
between the control or either of the two PQ/ Ubisol – Q10 groups and
the PQ3 group in each injection test phase are designated by * and
between the control and the PQ/Ubisol-Q10 8 weeks group and the
PQ3 in the second injection phase by ^.(p < 0.05) in the 1st test phase but only remained signifi-
cantly greater than that of the PQ3+/Ubisol-Q10 8 weeks
group in 2nd test phase (p = .036). Thus even though
the observed groups by phase interact was not signifi-
cant, multiple comparison between groups reveal that
only those rats that received Ubisol –Q10 in their drink-
ing water over the complete post injection period main-
tained their superior performance similar to that of rats
that were not exposed to potential neurodegenerative
effects of PQ. From a behavioral aspect, treatment with
the neuroprotectant agent only half way through the
post-injection period was not sufficient to maintain its
effect to the end of the experiment.
Toxicity assessment
The data presented above (Figure 4) clearly indicated that
long-term treatments with Ubisol – Q10 would be re-
quired to maintain the neuroprotection. To ensure safety
of such long treatments, we carried out a pilot toxicity
study, in which rats were maintained on drinking water
supplemented with Ubisol – Q10 at a dose 10 times higher
(60 mg/kg/day) than that used for neuroprotection (6 mg/
kg/day) for 2.5 months. During this time, the Ubisol – Q10
treated rats never displayed any signs of discomfort, no
change in eating, drinking, grooming habits and no differ-
ence in body weight in comparison with rats drinking
regular tap water over the same time period. At the con-
clusion of the experiments several tissues were collected
and sent for histopathological examination by a board cer-
tified pathologist at the University of Guelph. No overt le-
sions of toxicological significance were observed in the
Ubisol-Q10-treated animals (data not shown).
Discussion
For the first time ever, we have effectively established an
animal model, using PQ, which accurately demonstrates
the chronic and progressive neurodegeneration similar
to that in PD patients. Compared to an acute model, our
model effectively replicates PD by having slow, chronic
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sive neurodegeneration has also been observed with con-
tinuous infusion of MPTP using an osmotic pump [21].
The progressive loss was evident in our results over the
observed time span, with a decreased number of neu-
rons remaining at each subsequent time interval. Our
model allows us to intervene with treatment at any point
after the initiation of the disease. Due to this we were
also able to demonstrate for the first time, that when
Ubisol-Q10 is administered therapeutically it effectively
halts the progression of the neurodegeneration, even at
low dosages. After demonstrating the success Ubisol-Q10
has in protecting the neurons therapeutically, it was
shown that this treatment needs to be continuous. Halting
the administration of the treatment would result in a con-
tinuation of the neurodegeneration initiated by the PQ
toxin during the injection regime. With bioavailability
data, we were also able to show that Ubisol-Q10 is effective
at increasing the CoQ10 levels in the brain. All of the re-
sults were supported using behavioural, histochemical,
and biochemical methodology.
An animal model of PD was developed when the
neurotoxin MPTP was found to cause PD like symptoms
and loss of DA neurons by blocking complex I of the
electron transport chain [7]. MPTP establishes an acute
model of PD, which is not realistic to the natural pro-
gression of the disease. Following this, it was found that
environmental toxins, rotenone and PQ, can also block
complex I of the electron transport chain. Further sup-
ported by epidemiological studies, a link between the use
of these pesticides and the incidence of PD was estab-
lished [22]. The development of the PQ animal model of
PD is more relevant than the acute MPTP model as it
more effectively mimics PD in patients.
In previous research, a variety of dosages and injection
regimes of PQ have been used in rat models of PD
[14,23]. The downfall of these PQ models was that they
were not tested to ensure slow, progressive loss. How-
ever, progressive, continuous, and slow neuronal loss in
the SNpc was tested and seen in our model during and
after our 5 interpretational injection (1 every 5 days for
5 injections). Establishing this model is essential before
testing any therapeutic treatment interventions as this is
what characterizes PD in patients.
Additional research shows that the pathogenic mecha-
nisms of PD are associated with mitochondrial dysfunc-
tion, oxidative stress and altered protein handling [4]. The
involvement of mitochondria is considered a key to cell
death observed in PD in both sporadic and familial cases.
Previous experiments in our lab have shown that
Ubisol-Q10 is effective in protecting neurons against
toxic insult in vivo and can protect DA neurons if ad-
ministered prophylactically, that is, even before expos-
ure to the environmental toxin, PQ [14]. However, PD isoften not diagnosed until symptoms arise, which occurs
when almost 50 – 60% neurons are lost.
Once the process is initiated by toxic insult, it is cru-
cial to see if treatment administered therapeutically can
halt further neurodegeneration. Ubisol-Q10 was tested
therapeutically and it showed to have significant protec-
tion of the remaining DA neurons after both 4 weeks,
and 8 weeks of treatment. This is one of the first experi-
ments to show this. There are multiple explanations which
could explain how Ubisol-Q10 protects the remaining
neurons; initially it is plausible that the combined anti-
oxidant nature of the two components of Ubisol-Q10
(CoQ10 and Vitamin E) could quench the levels of oxida-
tive stress associated with the disease. It was shown that
the carrier solution containing vitamin E alone did not
have a significant effect on neuroprotection ([14] and data
not shown). In other research, it’s been shown that lipid
soluble CoQ10 (in high dosages) is an effective neuropro-
tective agent [19]. Past research on Ubisol-Q10 has shown
it to be effective in stabilizing the mitochondria through
inhibiting Bax [24]. Another hypothesis is that it could be
protecting the mitochondria by increasing its overall en-
ergy output; as CoQ10 is naturally found in the electron
transport chain.
Previous research using oil soluble CoQ10 as a treatment
for PD made it into clinical trials in 2011, though failed in
phase 2. In their pre-clinical work the oil-soluble CoQ10
treatment was tested prophylactically on MPTP induced
mouse model [19,25]. The oil soluble CoQ10 was shown to
be effective, but only at high dosages. A possible explan-
ation to the discontinuation of their clinical trial was be-
cause very large dosages (1,600 mg/kg/day) were required
to show any neuroprotection. When this dosage is con-
verted to a human dose (averaging 70 kg) they are re-
quired to take 112 g/day in order to obtain results, which
is beyond the acceptable FDA approved dose for clinical
trials (2.4 g). Therefore, in the clinical trial they were not
receiving anywhere near the dose required to show posi-
tive results. However, our preclinical work, on our more
accurate chronological model, treating both prophylactic-
ally and therapeutically has shown comparable neuropro-
tection but at a significantly lower dose (6 mg/kg/day).
Therefore, if our dosage was converted for human treat-
ment it would only be 0.42 g/day, which is not only lower
then FDA approved amount for clinical trial (2.4 g) but
also the approved maximum daily dosage for general sup-
plement intake (1.2 g). Both the oil soluble CoQ10 and
Ubisol-Q10 showed comparable bioavailability when ad-
ministered, but in order to have comparable quantities in
the brain the oil formulation needed to be given in a sig-
nificantly higher dose [26].
The question remains why Ubisol-Q10 is more effective
at lower doses than CoQ10. It is assumed that the water
soluble composition makes absorption into the blood
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blood brain barrier. It is evident in our bioavailability ex-
periment that this formulation does shuttle CoQ10 into
the brain, due to the increase of 35% after 3 hours.
Though, the other significant finding was that once it is in
the brain it does not accumulate. This means that there is
no build-up of CoQ10 in the brain, which could be toxic
to the neurons. The natural removal seen explains why
when the treatment is withdrawn the effects are no lon-
ger sustained. Henceforth, in order to sustain neuropro-
tection the treatment must be continuous and in doing
so neurotoxicity will not result. It is also important to
note that the animals in this experiment were allowed
to drink Ubisol-Q10 supplemented drinking water ad
libitum and were not gavaged.
Our study has shown that the withdrawal of Ubisol-Q10
leads to continued neurodegeneration, which was trig-
gered by the toxin during the injection period. Therefore,
Ubisol-Q10 does not halt neurodegeneration by acting on
the toxin, but rather by supporting the remaining neurons.
This experiment was only conducted with sustained treat-
ment over 8 weeks (with 1 month of treatment and a
consecutive month of withdrawal). To ensure the results,
more research needs to be conducted over longer time
spans. Though the current data found supports sustained
treatment regiments in order to withstand neurodegenera-
tion. These findings were also supported by the behaviour
data which shows that animals provided with Ubisol-Q10
treatment for a longer duration perform better throughout
in the beam test compared to the animals where the treat-
ment was withdrawn.
Conclusion
In conclusion we have shown that the PQ rat model of
PD we used in the study shows slow progressive loss of
DA neurons and hence mimics what is seen in patients
suffering from PD. Our formulation can prevent the
death of the remaining neurons in our PD model when
administered after the process of neurodegeneration has
been triggered and hence could be an effective therapeutic
at any stage of the disease. Also, we found that Ubisol-Q10
has to be given continuously and cannot be withdrawn in
order to continue neuroprotection. Bioavailability studies
have shown that even though this formulation is provided
at a low dose in order to provide significant neuroprotec-
tion, CoQ10 does cross the blood brain barrier and there is
an increase in the levels of CoQ10 in the brain following
administration of Ubisol-Q10. This formulation of CoQ10
is FDA-GRAS approved and preliminary toxicity results
show that there is no overt toxicity even when the dose is
increased to 10 times the required dose. Ubisol-Q10 is
an effective neuroprotective agent that could be used
effectively to halt the progression of Parkinson’s disease
at low doses.Methods
Animal care
All procedures involving animals were carried out in
accordance with the Canadian Council for Animal Care
guidelines and approved by the University of Windsor’s
Animal Care Committee. Three months old male Long
Evans Hooded rats were purchased from Charles River
Laboratories. Rats in the same treatment group were
housed together (3–4 per cage) for convenience and in
order to prevent any hierarchy that could arise due to
the extent of neurodegeneration. The rooms that housed
the rats were maintained at 20°C in a reversed 12 h:12 h
dark light cycle.
Paraquat neurotoxicity model and Ubisol-Q10 treatments
Rats received 5 intraperitoneal injections of PQ at a dose
of 10 mg/kg body weight/injection dissolved in phosphate
buffered saline (PBS), one injection every 5 days over a
period of 20 days. Control rats received intraperitoneal
injections of PBS alone. Brain tissue was examined im-
mediately after the last PQ injection and, subsequently,
4 weeks and 8 weeks later. Supplementation of drinking
water with Ubisol-Q10 at a concentration of 200 μg/ml
(equivalent to 50 μg CoQ10/ml) begun on the day of the
last PQ injection and it was continued for either 4 weeks
or 8 weeks. Fresh drinking solutions were provided
every second day. Sterile stock solution of Ubisol-Q10 at
200 mg/ml (equivalent to 50 mg CoQ10/ml) was pro-
vided by Zymes LLC (Hasbrouck, NJ). At the conclusion
of experimental treatments, rats were perfused with Tyr-
odes buffer containing heparin, the tissues were fixed with
10% formalin, and the brains extracted and stored in the
10% formalin until processing for immunohistochemistry.
CoQ10 bioavailability study
Rats were deprived of water for a period of 24 hours
prior to a full 1 h access to drinking water supplemented
with Ubisol-Q10 at a concentration equivalent to 50 μg
CoQ10/ml. The rats were sacrificed at 1, 3 and 6 h after
the feeding. Brain tissue was collected and CoQ10
content was measured as previously described [27-29].
Briefly, samples were homogenized in cold PBS and sub-
jected to repeated freezing/thawing steps to disrupt pro-
tein/lipid complexes. CoQ10 was extracted and analysed
by HPLC following separation on a TSK-GEL ODS-100S
column (4.6 mm× 150 mm, 7 μ particle size, TOSOH
Biosep LLC, Montgomeryville), equipped with a 1 mm
C18 guard column (Optimize Technologies Inc., Oregon
City, OR). Absorbance at 275 nm was monitored and re-
corded using Beckman System Gold Software.
Toxicity study
A group of rats (4 rats) were kept for 2.5 months on drink-
ing water supplemented Ubisol- Q10 at a concentration
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dose used in the neuroprotection study. Animals were
weighed once a week to ensure their health. The rats were
then perfused with heparin containing Tyrodes buffer and
formalin fixed tissue – heart, lung, liver and kidney were
sent to the Animal Health Laboratory, University of
Guelph. Hematoxylin & Eosin -stained histological sec-
tions of the tissues were evaluated by a board-certified
veterinary pathologist.
Rat horizontal beam walking test
All rats were assessed for performance on a horizontal
beam-walking test for motor skills/motor deficits as mea-
sured by leg slips. The aluminium beam was 1.68 metres
in length, 2 centimetres in width and 0.75 metres from the
ground. A mirror was placed behind the beam, measuring
1.78 metres in length and 0.3 metres in height. Four weeks
after the last injection, rats underwent one trial per day
for four consecutive days (one training trial and three test
trials). Eight weeks after the last injection another three test
trials were performed (one trial per day). In the training trial,
rats ran down the beam to the holding cage on a flat plat-
form three times, each time with different distances between
the holding cage and starting position. The first position was
a quarter of the beam length, the second was half, and the
last was the entire distance of the beam. This last distance is
where mice were placed for the subsequent test trails.
Rats received a small slice of apple in the holding cage
located on a table at the end of the beam. The rat had
up to 2 minutes to cross the beam. The test trials were
recorded using a standard video camera, located 2 me-
tres perpendicular to the beam. The number of hind leg
slips made from either leg during each test trial was later
noted from viewing the recorded video clips. The number
of limb slips for each rat was summed over the three test
sessions in each phase because rats made too few slips in
each session to analyse this behaviour over trials within
each session. The statistical analysis of each rat’s total
number of leg slips over each test series was carried by a
two-way ANOVA (Groups x Test phase with repeated mea-
sures on the second factor). Effects from these analyses were
considered significant at p < 0.05. Post-hoc comparisons be-
tween groups at each test phase were carried out by Least
Squares Difference post-hoc multiple comparisons test mul-
tiple comparisons and significant differences between groups
were considered at p < 0.05 (one-tail) based on the prediction
that rats not given post-injection Ubisol-Q10 in their drinking
water would show deficits associated with PQ-induced
neurodegeneration.
Immunohistochemistry
The brains kept in 10% formalin were transferred to 30%
sucrose (w/v) three days before sectioning. The midbrain
region was sectioned at a thickness of 30 μm and 64sections were collected in total. The sections were sub-
jected to immunohistochemistry with anti-tyrosine hy-
droxylase antibody (1:1000 dilution) purchased from Pel-
Freeze Biologicals, USA. Prior to overnight incubation
with the primary antibody at 4°C, the sections were incu-
bated in 1% H2O2 for 5 minutes to block endogenous per-
oxidase, DAKO universal blocking solution (purchased
from Diagnostics Canada Inc., Mississauga) for 30 minutes
and in normal goat serum (prepared as per instructions
on anti-rabbit Vecstatin ABC Kit, Vector Laboratories) for
30 minutes in order to block the binding of non-specific
goat IgG. The sections were washed in Tris buffered saline
(TBS) twice for 5 minutes between the blocking steps in
order to remove any excess blocking reagents. After over-
night incubation the slides were washed in TBS twice and
incubated in biotinylated anti-rabbit IgG raised in goat
(anti-rabbit Vecstatin ABC Kit) for 1.5 hours. The slides
were again washed twice for 5 minutes with TBS, fol-
lowing which they were incubated in avidin biotin com-
plex (ABC reagent) for 45 minutes. Then the two five
minute washes with TBS were repeated, and the peroxidase
substrate 3, 3′ diaminobenzidine (DAB) prepared as per the
instructions to specifically stain the DA neurons. The sec-
tions were then dehydrated with 95% ethanol and xylene and
coverslipped to be able to visualise under the microscope.
The number of TH-positive neurons in the SN were
counted using the Stereology Software provided by the
Stereology Resource Center, Chester, MD as previously
described [30,31]. The SN region was outlined at low
magnification and the neurons were counted at high
magnification.
Statistical analysis
Differences among means were analysed using one way
analysis of variance (ANOVA) and pairwise comparisons
between means were analyzed by post hoc Bonferroni’s
multiple comparison test. The software used was Graph-
Pad Prism ver. 4.0.
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